Dr Aude Chapuis is an oncologist who sees patients in the Bone Marrow Transplant and Immunotherapy services. She leads a laboratory employing a translational pipeline to improve T cell receptor (TCR) gene-engineered immunotherapy. Their work spans target identification, generation of high-affinity TCR constructs and standard operating methods to translate these constructs into effective cell products for patients, clinical trial development and initiation, and sophisticated high dimensional immune-monitoring to maximize the information that can be derived from each treated patient. Current projects include T cell therapies against virally-driven tumors (targeting Merkel-cell polyoma virus antigens in Merkel cell carcinoma), solid tumors (targeting the MAGE-A1 cancer-testis antigen in non-small cell lung cancer, triple negative breast cancer, and bladder cancers; and targeting WT1 antigen in thoracic and gynecological cancers), and leukemias (targeting two WT1 epitopes in acute myeloid leukemia). The lab benefits from a highly collaborative network at the Fred Hutch, including expert investigators in basic science, cancer immunology and immunotherapy, as well as disease-specific clinical oncologists.
Chapuis AG, Egan DN, Schmitt TM, McAfee MS, Paulson KG, Voillet V, Gorttardo R, Ragnarsson GB, Bleakley M, Yeung CC, Mulhauser P, Nguyen HN, Kropp LA, Castelli L, Wagener F, Hunter D, Lindberg M, Cohen K, Seese A, McElrath J, Duerkopp N, Gooley TA, Greenberg PD. T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant.
Paulson KG, Voillet V, McAfee MS, Hunter DS, Wagener FD, Perdicchio M, Valente WJ, Koelle SJ, Church CD, Vandeven N, Thomas H, Colunga AG, Iyer JG, Yee C, Kulikauskas R, Koelle DM, Pierce RH, Bielas JH, Greenberg PD, Bhatia S, Gottardo R, Nghiem P, Chapuis AG. Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA.
Chapuis AG, Desmarais C, Emerson R, Schmitt TM, Shibuya K, Lai I, Wagener F, Chou J, Roberts IM, Coffey DG, Warren E, Robbins H, Greenberg PD, Yee C. Tracking the Fate and Origin of Clinically Relevant Adoptively Transferred CD8+ T Cells In Vivo.